Xiaflex (collagenase clostridium histolyticum)

Xiaflex is covered only for FDA‑approved uses—adult Dupuytren’s contracture with a palpable cord and baseline MCP/PIP contracture ≥20°, and adult Peyronie’s disease with a palpable plaque and baseline curvature ≥30° (or ≥15° if previously treated) —and is excluded for non‑FDA indications, insufficient baseline measurements, or prior completion of a full 8‑injection Peyronie’s course. Approval requires age ≥18, documentation of baseline degree and palpable cord/plaque, administration by experienced providers, and strict adherence to dosing/schedule limits (0.58 mg per injection; Dupuytren’s: ≤3 injections per cord, ≤2 cords per visit, ≥4 weeks between injections, 3‑month approval; Peyronie’s: up to 8 injections per course as four 2‑injection cycles with 1–3 days between injections and ~6 weeks between cycles, 6‑month approval).

"Peyronie's dosing: The dose of Xiaflex is 0."